Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric PopulationPatricia D. Maglalang, Lauri Filar, Jia‐Yuh Chen et al.|Clinical Pharmacokinetics|2024Cited by 5
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and InfantsSean McCann, Daniel González, Victória Etges Helfer et al.|The Journal of Clinical Pharmacology|2024Cited by 3
Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World DataSean McCann, Daniel González, Victória Etges Helfer et al.|Clinical and Translational Science|2025Cited by 3
Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without ObesitySean McCann, Daniel González, Jiali Wen et al.|The Journal of Clinical Pharmacology|2025Cited by 1
Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with ObesityJaydeep Sinha, Sasidharan Taravath, Kanecia O. Zimmerman et al.|Clinical Pharmacokinetics|2025Cited by 0